

support

universidade de aveiro



theoria poesis praxis

research

# Health & Biomedicine

## European Funding Opportunities 2018-2020

**Tatiana Costa**

**Research Support Office**

Vice-Rectorcy for Research and Doctoral School

University of Aveiro

January 2018






## The rationale behind this session...


Já submeteu propostas a projetos europeus/ Have you submitted any proposals to EU projects?

24 responses




Já participou/ Participa em projetos europeus/ Have you participated/ Are you participating in an EU project?

24 responses



Está a preparar, atualmente, alguma proposta a financiamento europeu/ Are you currently working on a proposal to EU funding?

24 responses



## The rationale behind your participation in this session ... I want ...

- money to develop my research team
- money to sustain my existing team
- to be a partner on a European research project
- To lead a European consortium
- To build my European research network
- To start linking with industrial partners
- To develop a technology or develop a product
- To second my staff to industry and vice-versa
- to be internationally recognised for my research
- Etc...



# European Funding at a glance


**Interreg Programmes**  
**(European Territorial Cooperation (ETC) )**

- cross-border (Interreg A) – **Spain-Portugal ( POCTEP)**
- transnational (Interreg B) - **Europe**
- interregional (Interreg C) – **SUDOE, MED, Atlantic Area**


**National /Regional Programmes**

ACTIVITIES

PROGRAMMES INCLUDING FUNDS FOR R&I ACTIVITIES



PROGRAMMES CONNECTED TO R&I ACTIVITIES



**COST**  
**Eurostars**  
 ...

ECSC Treaty legacy  **RFCS** 319

\* Budget for 2014-2018

Data source: [Multiannual Financial Framework](#), European Commission, 2015.

https://eprints.uevora.pt/handle/10448/10448



support

universidade de aveiro



theoria poiesis praxis

research

## H2020 in a nutshell

# Horizon 2020 Structure




**Researchers driven:**  
 Excellent science is the foundation of tomorrow's technologies, jobs and wellbeing

**Industry driven:**  
 Strategic investments in key technologies  
 Support to innovative companies

**Society driven:**  
 Address concerns of citizens and society/EU policy objectives  
 Multidisciplinary collaborations

European Institute of Innovation & Technology (EIT) • Joint Research Centre (JRC)  
 • Spreading Excellence and Widening Participation • Science with and for Society

# Coverage of the full innovation chain



## From the WP to the proposal

### Work Programme ( Biannual)

#### Topics

- Challenge
- Focus
- Impact

#### Actions

- Research & Innovation
- Innovation
- Coordination and Support



## Types of Action, Funding Rates and so on...

| Action Type  | Applicants  | Activities funded   | Eligibility  | Funding                            | overheads   |
|--|---|---|--|------------------------------------|---|
| <b>Research and Innovation Actions – RIA</b><br>(collaborative projects) | Research Institutes,<br>Higher Educations<br>Institutions,<br>Companies | R&D;<br>Innovation;<br>Management;<br>Others (training, dissemination & exploitation) | 3 legal entities established in Member States or Associated Countries that are different and independent of each other | 100%                               | 25% (over direct costs, excluding subcontracting) |
| <b>Innovation Actions – IA</b><br>(collaborative projects)               | Research Institutes,<br>Higher Educations<br>Institutions,<br>Companies | R&D;<br>Innovation;<br>Management;<br>Others (training, dissemination & exploitation) | 3 legal entities established in Member States or Associated Countries that are different and independent of each other | 70% (100% for non profit entities) | 25% (over direct costs, excluding subcontracting) |
| <b>Coordination and Support Actions – CSA</b>                            | Research Institutes,<br>Higher Educations<br>Institutions,<br>Companies | Management;<br>Networking;<br>Others (training, dissemination & exploitation)         | 1 legal entity established in Member States or Associated Countries  | 100%                               | 25% (over direct costs, excluding subcontracting) |
| <b>SME instrument</b>  | SME ( subcontracts as a possibility)                                    | Innovation;<br>Management;<br>Others (training, dissemination & exploitation)         | 1 SME established in Member States or Associated Countries   | 70%                                | 25% (over direct costs, excluding subcontracting) |

support

universidade de aveiro



theoria poesis praxis

research

## Health in H2020



Horizon 2020 is the EU's research and innovation funding programme



# Horizon 2020 HEALTH research and innovation funding

An investment in better health for all

more than 10 billion  
2014-2020



15 funding channels

to meet specific health research and innovation needs

Includes support for individual grants and fellowships, SMEs, large collaborative public-private consortia

## INVESTMENT IN RESEARCH AND INNOVATION AIMS TO IMPROVE THE QUALITY OF LIFE FOR EU CITIZENS



sustain health and care systems



provide innovative solutions addressing the main challenges through collaborative research



stimulate the entire health R&I cycle from bench to bedside and the rapid transfer of knowledge



increase Europe's competitiveness, prosperity and wellbeing



support global sustainable development



support the generation of a health research cloud

[http://ec.europa.eu/research/images/infographics/health/h2020\\_health\\_funding\\_2017-w920.jpg](http://ec.europa.eu/research/images/infographics/health/h2020_health_funding_2017-w920.jpg)



# 5 Areas – 5 modalities



## COLLABORATIVE RESEARCH

Support multidisciplinary and cross-sector research on health and care for generating and translating new knowledge into applications and benefits for the society



## Pilar 3 – SC 1

[http://ec.europa.eu/research/images/infographics/health/h2020\\_health\\_funding\\_2017-w920.jpg](http://ec.europa.eu/research/images/infographics/health/h2020_health_funding_2017-w920.jpg)

# 5 Areas – 5 modalities

## ◆ INNOVATIVE HEALTH AND CARE INDUSTRY Translate innovation into practical health and care applications benefiting citizens, healthcare systems and businesses

**INNOVATIVE MEDICINE INITIATIVE (IMI) \***

 To offer grants towards the development of patient access to personalised medicine for the health and wellbeing of all, especially in areas of unmet medical need

**PARTICIPATION** 

**FUNDING** 

**CUSTOMER** Academic institutions | SMEs and research organisations | large pharmaceutical companies | patient organisations | NGOs | public bodies

**SME INSTRUMENT Pilar 2**

 To support individual highly innovative SMEs via competitive grants

**PARTICIPATION** 

**FUNDING** 

**CUSTOMER** SMEs

**FAST TRACK TO INNOVATION (FTI)**

 To provide grants to bottom-up proposals for close-to-market innovation activities

**PARTICIPATION** 

**FUNDING** 

**CUSTOMER** SMEs | industry | academic institutions

**INNOVFIN INFECTIOUS DISEASES (INNOVFIN ID)**

 To provide loans to support bankable development of innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for infectious diseases

**PARTICIPATION** 

**FUNDING**  but clinical studies can also be supported in 

**CUSTOMER** Small and big R&D companies and any other entity that can take loans (EUR 7.5m to EUR 75m)

**EIT HEALTH \***

 To provide grants to increase competitiveness of European industry, improve the quality of life of Europe's citizens and the sustainability of healthcare systems

**PARTICIPATION** 

**FUNDING** 

**CUSTOMER** Legal entities interested in mixing research, innovation and education

**HORIZON PRIZES \***

 To offer a cash reward to whoever can most effectively meet a defined challenge

**PARTICIPATION** 

**FUNDING** 

**CUSTOMER** Any individual or legal entity who can meet the challenge

[http://ec.europa.eu/research/images/infographics/health/h2020\\_health\\_funding\\_2017-w920.jpg](http://ec.europa.eu/research/images/infographics/health/h2020_health_funding_2017-w920.jpg)



# 5 Areas – 5 modalities

## WORKING WITH MEMBER STATES AND INTERNATIONAL PARTNERS Foster European and global coordination in health and disease research



The infographic details four modalities for working with member states and international partners:

- EUROPEAN AND DEVELOPING COUNTRIES CLINICAL TRIALS PARTNERSHIP (EDCTP):**
  - Objective:** To support clinical trials, diagnostics and delivery optimisation for poverty-related and neglected infectious diseases via grants.
  - Participation:** Represented by icons of people and a globe.
  - Funding:** Includes AC (Action Grant) and funding from the EU and Africa (with a map of sub-Saharan Africa).
  - Customer:** All legal entities.
- ACTIVE AND ASSISTED LIVING PROGRAMME (AAL):**
  - Objective:** To offer grants towards improving conditions of life for the older adults and strengthening the international industrial opportunities in the area of information and communication technology.
  - Participation:** Represented by icons of people and a globe.
  - Funding:** Includes AC (Action Grant) and funding from AAL member states.
  - Customer:** Sectors interested in market-oriented research.
- ERA-NET:**
  - Objective:** To provide grants to support public-public partnerships in their preparation, implementation and coordination of joint activities as well as topping up of single joint calls and of actions of a transnational nature.
  - Participation:** Represented by icons of people and a globe.
  - Funding:** Includes AC (Action Grant) and funding from the EU.
  - Customer:** National/regional ministries/authorities managing research programmes | research councils or funding agencies or other national or regional organisations that implement research programmes.
- JOINT PROGRAMMING INITIATIVES:**
  - Objective:** EU Member States driven initiatives offering grants to increase coordinated investment in research between participating countries.
  - Participation:** Represented by icons of people and a globe.
  - Funding:** Rules of the JPI | call specific conditions apply.
  - Customer:** All legal entities.

<http://www.edctp.org/>

<http://www.aal-europe.eu/>

<https://www.fct.pt/apoios/cooptrans/eranets/>

<http://www.neurodegenerationresearch.eu/>  
<https://www.jpimr.eu/>  
<http://www.jp-demographic.eu/calls/>

http://ec.europa.eu/research/images/infographics/health/h2020\_health\_funding\_2017-w920.jpg



# 5 Areas – 5 modalities

## BLUE SKY RESEARCH Reinforce and extend the excellence of the EU's science base (including in life sciences and health-related research)

|   |  |   |
|---|--|---|
| <p><b>EUROPEAN RESEARCH COUNCIL (ERC)</b> *</p> <p>To promote investigator-driven, or bottom-up frontier research via grants</p> <p><b>PARTICIPATION</b> </p> <p><b>FUNDING</b>  </p> <p><b>CUSTOMER</b> Largely targeted at academics</p> | <p><b>FUTURE AND EMERGING TECHNOLOGIES (FET)</b> *</p> <p>To offer grants for developing new lines of technology through unexplored collaborations between advanced multidisciplinary science and cutting-edge engineering</p> <p><b>PARTICIPATION</b>  </p> <p><b>FUNDING</b>   </p> <p><b>CUSTOMER</b> All legal entities</p> | <p><b>MARIE SKŁODOWSKA-CURIE ACTIONS (MSCA)</b> *</p> <p>To provide grants for all stages of researchers' careers and encourage transnational, intersectoral and interdisciplinary mobility</p> <p><b>PARTICIPATION</b>  </p> <p><b>FUNDING</b>   </p> <p><b>CUSTOMER</b> Pre-doctoral and post-doctoral researchers in the academic   industrial sectors</p> |
|---|--|---|

### Pilar 1

**INFRASTRUCTURES**  
Support facilities, resources and services used by the science community to conduct research and foster innovation (including in the health area)

**12 EUROPEAN STRATEGY FORUM ON RESEARCH INFRASTRUCTURES (ESFRI) PROJECTS IN THE HEALTH RESEARCH AREA**

To support facilities, resources and services used by the science community, to conduct research and foster innovation in the biological and medical areas

**PARTICIPATION**  

**FUNDING**   

**CUSTOMER** Academic institutions | research organisations | public bodies

[http://ec.europa.eu/research/images/infographics/health/h2020\\_health\\_funding\\_2017-w920.jpg](http://ec.europa.eu/research/images/infographics/health/h2020_health_funding_2017-w920.jpg)

support

universidade de aveiro



theoria poiesis praxis

research

## Overview of the opportunities in WP 2018-2020



## Work Programmes 2018-2020 – New features

LEIT-NMBP, LEIT-Space, SC1, SC2, SC3, SC4 and SC5

Building a low carbon, climate resilient future

Digitising and transforming European industry and services

*LEIT-ICT, LEIT-NMBP, LEIT-Space, Societal Challenges 1, 2, 4 and 6.*

Focus Areas

Connecting economic and environmental gains – the Circular Economy

Boosting the effectiveness of the Security Union

*LEIT-NMBP, and Societal Challenges 2, 3 and 5.*

*LEIT-ICT, LEIT-Space and Societal Challenges 6 and 7.*



support

universidade de aveiro



theoria poesis praxis

research

## Pilar 1


Excellent Science

European Research Council (ERC)

Future Emerging Technologies (FET)

Marie Skłodowska Curie Actions (MSCA)

European Research Infrastructures



# Pilar 1 – European research Council (ERC)

## Starting Grants

are designed to support excellent Principal Investigators at the early stage at which they are beginning their own independent research team in a new programme.

(2 years after PhD)

Cut-off dates:  
 PhD awarded from 1 January 2011 to 31 December 2015 (inclusive))

**Expected – August 2018?**

## Consolidator Grants

(7-12 years after PhD)

Open - 24/10/2017 to 15/02/2018

Cut-off dates:  
 from 1 January 2006 to 31 December 2010 (inclusive))

**Open - 24/10/2017 to 15/02/2018**

## Advanced Grants

designed to support excellent Principal Investigators at an advanced career stage at which they have already established an independent research team and a recognised record of significant research achievements in the last 10 years

**Expected – 17/05/2018 to 30/08/2018**


**Synergy Grants** – enable 2- 4 PI's ( complementary skills, knowledge, and resources) and their teams to bring their expertise to bear in new ways, in order to jointly address significant and ambitious research problems.

**Expected – 03/08/2018 to 14/11/2018**

**OPEN 6/09/2017 to 16/01 | 18/04 | 11/09 2018**

Proof-of-Concept bridging innovation up to €150,000 – earliest stage of marketable

# Pilar 1 – ERC@UA profile 2017



\* on going evaluation process

## Pilar 1 – FET (EIC)

**Future and emerging technologies** shall support collaborative research in order to extend Europe's capacity for **advanced and paradigm-changing innovation**. It shall foster scientific **collaboration across disciplines** on **radically new, high-risk ideas** and accelerate development of the most promising emerging areas of science and technology as well as the Union wide structuring of the corresponding scientific communities."

### FET Open

- Exploring novel ideas

#### Open (RIA)

1st cut-off – 16 may 2018

2nd cut-off – january 2019

#### Open (CSA)

1st cut-off – 11 april 2018

2nd cut-off – 16 october 2018

- Bottom-up

### FET Proactive

- Developing topics and communities – cluster of research projects
- Global System Sciences
- Knowing, doing being-cognition beyond problem solving
- Quantum simulation
- Towards exascale high performance computing

### FET Flagship

- Tackling grand interdisciplinary science and technology challenges
- Graphene
- Human Brain (HBP)
- *Support for Flagships*

Open, light and agile

Roadmap based research



## Pilar 1 – FET ( Open)

### RIA


to lay **the foundations for radically new future technologies** of any kind from **visionary interdisciplinary collaborations** that **dissolve the traditional boundaries between sciences and disciplines**, including the social sciences and humanities. This topic also encourages the driving role of **new actors in research and innovation, including excellent young researchers, ambitious hightech SMEs and first time participants to FET** under Horizon 2020 from across Europe.

Proposals are sought for **cutting edge high risk / high impact** interdisciplinary research

### CSA

to promote excellent collaborative research and innovation on future and emerging technologies to secure and renew the basis for future European competitiveness and growth, and that will make a difference for society in the decades to come

- FET Communication and Outreach
- FET Innovation
- FET Observatory



### A typical Research and Innovation Action project



Average funding per project:  
**3.4 million €**



Average number of partners per project:  
**6**



Average project duration:  
**41 months**

## Pilar 1 – FET ( flagships)

FETFLAG-01-2018: Preparatory Actions for new FET Flagships

NOW OPEN – 31<sup>st</sup> October 2017 to 20 February 2018 ( 1<sup>st</sup> stage)  
2<sup>nd</sup> stage – 18 September 2018


Proposals should contain a description of a potential FET Flagship and how this is to be matured over the course of the preparatory action into a more complete blueprint.(...)  
Proposals for candidate FET Flagships must target a visionary unifying goal within one of the following three main areas:

- ICT and Connected Society - Smart Materials and Nanoscale Engineering:
- **Health and Life Sciences;**
- Energy, Environment and Climate change - Radically new Energy Production, Conversion and Storage devices and systems:

They should present a multidisciplinary approach that brings together the relevant communities to address their unifying goal.


- **Disruptive technologies to Revolutionise Healthcare**
- **Understanding Life by Exploring the Genome and the Cell:**

## Pilar 1 – MSCA - General Features



- Ensure excellent and innovative research training as well as attractive career and knowledge-exchange opportunities through **cross-border and cross-sector mobility** of researchers/innovation staff
- Open to **all domains** of research and innovation /from basic to applied research (bottom-up approach)
- Open to researchers/innovation staff at **all career stages**
- Open to universities, Research institutions, Research infrastructures, **businesses**, other socio-economic actors
- Open to MS and third countries
- Operate in a 'bottom-up' basis , covering all scientific domains
- Strong accent on participation of industry, SMEs and non-academia overall

## Pilar 1 – MSCA- calls

|   |   |  |
|---|---|--|
| <b>ITN - Innovative Training Networks</b>                                     | <b>Support for doctoral and early-stage training</b><br><b>European Training Networks (ETN), European Industrial Doctorates (EID), European Joint Doctorates (EJD)</b><br><br><i>Indicative dates 12 Oct 2017 – 17 jan 2018</i>   |  <p>Host-driven!</p>                                  |
| <b>IF- Individual Fellowships</b>   | <b>Support for experienced researchers undertaking international and inter-sector mobility:</b><br><b>European Fellowships and Global Fellowships</b><br><b>Dedicated support for career restart and reintegration</b><br><br><i>Indicative dates 12 Apr 2018 – 12 set 2018</i> |  <p>Individual-driven!</p>                            |
| <b>RISE - Research and Innovation Staff Exchange</b>                          | <b>International and inter-sector cooperation through the exchange of staff</b><br><br><i>Indicative dates 22 nov 2017 – 21 mar 2018</i>  |  <p>Host-driven!</p>                                 |
| <b>COFUND - Co-funding of regional, national and international programmes</b> | <ul style="list-style-type: none"> <li>- Doctoral programmes</li> <li>- Fellowship programmes</li> </ul><br><i>Indicative dates 12 apr 2017 – 27 sept 2018</i>  |  <p>Institutional (strategic, only 50% funding)</p> |

- **Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology (NMBP's)**
- **Space**
- **ICT**

## Pilar 2

### Industrial Leadership

Enabling and Industrial Technologies

Access to Risk Finance

Innovation in SMEs



## Pilar 2 – LEIT - Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology ( NMBP's)

### Foundations for tomorrow's Industry

- **Open Innovation Test Beds**
- **Materials characterization and Computational Modelling**
- **Governance, Science-based risk assessment and regulatory aspects**

### Transforming European Industry

- **Factories of the Future ( FoF)**
- **Biotechnology**
- **Medical Technical Innovations**

### Industrial Sustainability

- **Sustainable Process Industry ( SPIRE)**
- **Catalysing the circular economy**
- **Clean energy through innovative materials**
- **Cultural heritage**
- **Energy-Efficient buildings (EEB)**



## Pilar 2 – LEIT-Foundations for tomorrow's Industry

| Call Identifier  | Tipo de ação | Specific Challenge/Scope   | Deadlines                    |
|--|--------------|--|------------------------------|
| <b>DT-NMBP-03-2019:<br/>Open Innovation Test Beds for nano-enabled surfaces and membranes</b>    | IA           | The challenge is to enable a cost effective and sustainable industrial upscaling and deployment of nano-enabled surface and membrane technologies ( ...)bio-functionality, bio-compatibility, control of reflectivity, sensing ability, self-cleaning, antimicrobial, permeability and selectivity properties(...) | 16 Oct 2018<br>- 22 Jan 2019 |
| <b>DT-NMBP-04-2020:<br/>Open Innovation Test Beds for bio-based nano-materials and solutions</b> | IA           | to be published  | to be defined                |
| <b>DT-NMBP-06-2020:<br/>Open Innovation Test Beds for nano-pharmaceuticals production</b>        | IA           | to be published  | to be defined                |
| <b>NMBP-17-2020:<br/>Regulatory science for medical technology products</b>                      | RIA          | to be published  | to be defined                |



## Pilar 2 – LEIT-Transforming European Industry

| Call Identifier   | Tipo de ação | Specific Challenge/Scope | Deadlines     |
|---|--------------|--------------------------|---------------|
| BIOTEC-07-2020:<br><b>Multi-omics for the optimisation of genotype-phenotype associations</b> | RIA          | to be publicated         | to be defined |
| DT-NMBP-23-2020:<br><b>Next generation organ-on-chip</b>                                      | RIA          | to be publicated         | to be defined |





## The obvious...

## Pilar 3

### Societal Challenges

Health, Demographic Change and Wellbeing

Food Security, Sustainable Agriculture, etc.

Secure, Clean and Efficient Energy

Smart, Green and Integrated Transport

Climate Action, Resource Efficiency and Raw Materials

Inclusive, Innovative and Reflective Societies

Secure Societies





## Pilar 3 – DS1 Health, demographic change and wellbeing

### Better Health and Care, economic growth and sustainable health (BHC)

- Personalised medicine
- Innovative health and care industry
- Infectious diseases and improving global health
- Innovative health and care systems – integration of care
- Decoding the role of the environment for health and well-being

### Digital transformation in Health and Care (DTH)

- Enable better access to healthcare for patients
- Ensure the sustainability of health and care systems

### Trusted digital Solution and Cybersecurity in health and care

- Strong contribution to focus áreas Digitising and transforming European industry and services and Boosting the effectiveness of the Security Union.





[http://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-2020/main/h2020-wp1820-health\\_en.pdf](http://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-2020/main/h2020-wp1820-health_en.pdf)



### Pilar 3 – DS1 – Personalized Medicine & Innovative Health and care industry

28 jul 2018 to 2 oct 2018 ( 2 stage!)

SC1-BHC-01-2019: Understanding causative mechanisms in **co- and multimorbidities**.....  
SC1-BHC-02-2019: **Systems approaches** for the discovery of **combinatorial therapies for complex disorders** .....

deadline 18 apr 2018

SC1-BHC-03-2018: Exploiting research outcomes and application potential of the **human microbiome for personalised prediction, prevention and treatment of disease**.....  
SC1-BHC-05-2018: International flagship **collaboration with Canada for human data storage, integration and sharing to enable personalised medicine approaches** .....

Call repeats annually

SC1-HCO-01-2018-2019-2020: Actions in support of the **International Consortium for Personalised Medicine**.....

deadline 18 apr 2018

SC1-HCO-02-2018: **Data integration and data-driven in-silico models for enabling personalised medicine - a European standardization framework**.....

RIA

CSA

28 jul 2018 to 2 oct 2018 ( 2 stage!)

SC1-BHC-07-2019: **Regenerative medicine**: from new insights to new applications.....

SC1-BHC-09-2018: Innovation platforms for **advanced therapies** of the future .....

SC1-HCO-05-2018: Strengthening **regulatory sciences and supporting regulatory scientific advice** .....

RIA

CSA



### Pilar 3 – DS1 – Infectious diseases and Improving Global Health

- SC1-BHC-13-2019: Mining **big data** for **early detection of infectious disease** threats driven by **climate change and other factors**.....
- SC1-BHC-14-2019: Stratified **host-directed approaches** to improve **prevention, treatment and/or cure of infectious diseases**.....
- SC1-BHC-15-2018: New **anti-infective agents for prevention and/or treatment of neglected infectious diseases (NID)**.....
- SC1-BHC-16-2018: Global Alliance for Chronic Diseases (GACD) - Scaling-up of **evidence-based health interventions at population level** for the **prevention and management of hypertension and/or diabetes**.....
- SC1-BHC-18-2018: **Translational collaborative cancer research** between **Europe** and the Community of **Latin American and Caribbean States (CELAC)**.....



## Pilar 3 – DS1 – Infectious diseases and Improving Global Health

- SC1-BHC-13-2019: Mining **big data** for **early detection of infectious disease** threats driven by **climate change and other factors**.....
- SC1-BHC-14-2019: Stratified **host-directed approaches** to improve **prevention, treatment and/or cure of infectious diseases**.....
- SC1-BHC-15-2018: New **anti-infective agents for prevention and/or treatment of neglected infectious diseases (NID)**.....
- SC1-BHC-16-2018: Global Alliance for Chronic Diseases (GACD) - Scaling-up of **evidence-based health interventions at population level** for the **prevention and management of hypertension and/or diabetes**.....
- SC1-BHC-18-2018: **Translational collaborative cancer research** between **Europe** and the Community of **Latin American and Caribbean States (CELAC)**.....
- SC1-BHC-19-2019: Implementation **research for maternal and child health**.....
- SC1-BHC-21-2018: **Research on HIV, tuberculosis (TB) and/or hepatitis C (HCV)** in patients with mono-, co-infections and/or comorbidities in the context of fostering collaboration with the Russian Federation.....
- SC1-HCO-06-2018: Establishment of an International Network of Social Sciences Research Centres to help address governance and other challenges in the preparedness for and the response to infectious threats.....
- SC1-HCO-08-2018: Creation of a **European wide sustainable clinical research network for infectious diseases**.....
- SC1-HCO-09-2018: Building international efforts on **population and patient cohorts**.....
- SC1-HCO-10-2018: Coordinating European brain research and developing global initiatives.....
- SC1-HCO-11-2018: Strategic collaboration in **health research and innovation** between **EU and China**.....

**Pilar 3 – DS1 – Innovative health and care systems – integration of care**

SC1-BHC-22-2019: **Mental health in the workplace**..... 5

SC1-BHC-23-2018: Novel patient-centred approaches for **survivorship, palliation and/or end-of-life care**..... 5

SC1-BHC-25-2019: **Demonstration pilots for implementation of personalised medicine in healthcare** ..... 5

SC1-BHC-26-2018: HTA research to support evidence-based healthcare..... 5

SC1-HCO-12-2018: Innovation in healthcare - a CSA towards using pre-commercial procurement and public procurement of innovative solutions in healthcare systems..... 5

**Pilar 3 – DS1 Decoding the role of the environment for health and well-being**

SC1-BHC-27-2018: New **testing and screening methods to identify endocrine disrupting chemicals**.....

SC1-BHC-28-2019: The **Human Exposome Project: a toolbox for assessing and addressing the impact of environment on health**.....

SC1-HCO-13-2018: Setting the priorities for a European environment, climate and health research agenda ..... 5

### Pilar 3 – DS1 Digital transformation in Health and Care

- SC1-DTH-01-2019: Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment .....
- SC1-DTH-03-2018: Adaptive smart working and living environments supporting active and healthy ageing .....
- SC1-DTH-05-2019: Large scale implementation of digital innovation for health and care in an ageing society .....
- SC1-DTH-07-2018: Exploiting the full potential of in-silico medicine research for personalised diagnostics and therapies in cloud-based environments .....
- SC1-DTH-08-2018: Prototyping a European interoperable Electronic Health Record (EHR) exchange .....
- SC1-DTH-09-2019: Scaling up the univocal Identification of Medicinal Products .....
- SC1-DTH-10-2019-2020: Digital health and care services .....
- SC1-DTH-11-2019: Large Scale pilots of personalised & outcome based integrated care .....
- SC1-HCC-01-2018: Supporting investment in smart living environments for ageing well through certification .....
- SC1-HCC-02-2019: Support for the large scale uptake of open service platforms in the Active and Healthy Ageing domain .....
- SC1-HCC-03-2018: Support to further development of international cooperation in digital transformation of health and care .....
- SC1-HCC-04-2018: Digital health and care services – support for strategy and (early) adoption .....
- SC1-HCC-05-2018: Support to a Digital Health and Care Innovation initiative in the context of Digital Single Market strategy .....

support

universidade de aveiro



theoria poiesis praxis

research

## H2020 - Transversal Programmes



## Spreading Science and Widening Participation

Disparities in research and innovation performance: barrier to competitiveness, growth and jobs across Europe

Some countries experience low participation in the EU Framework Programmes because of:

- insufficient national R&D investments
- lack of synergies between national research systems and the EU research landscape
- system learning effects
- reduced access to international networks
- problems with information, communication and training

- **Transfer of knowledge;**
- **Institutions enhancement;**
- **Links with Smart Specialisation;**
- **leading role in creating the innovative eco-system;**
- **Synergies with ESIF;**

**Institucional Building**

**TEAMING**

Creation of new (or significant upgrade of existing) Centres of Excellence in low R&I performing or "Widening" countries

**Institucional Networking**

**TWINNING**

Strengthen a defined field of research in a university or research organisation from a Widening country by linking it with at least two internationally-leading research institutions

**15 may 2018- 15 nov 2018**

**bringing excellence to institutions**

**ERA Chairs**

Bring high quality researchers and managers (the ERA Chair and his/her team) to universities and other research organisations with the potential for research excellence.

**26 jul 2018 – 15 nov 2018**

**NCP's -**  
(information, communication, support)


**Policy Support Facility –**  
support for R&I Policy design

**COST –**  
stimulating cross border science networks

## Science with and for Society

The specific objective is to build effective cooperation between science and society, to recruit new talent for science and to pair scientific excellence with social awareness and responsibility.

1. Institutional Change to support RRI in Research Performing and Funding Organisations
2. Embedding RRI in H2020 R&I
3. Strengthening the SWAFs Knowledge-Base
4. Developing Inclusive, Anticipatory Governance for R&I
5. Other actions



WP 2018-2020  
5 priorities , 22 calls

[http://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-2020/main/h2020-wp1820-swfs\\_en.pdf](http://ec.europa.eu/research/participants/data/ref/h2020/wp/2018-2020/main/h2020-wp1820-swfs_en.pdf)



## Horizon Prizes ( EIC)

OPEN: 4<sup>th</sup> QUARTER 2017 | CLOSE: 3<sup>rd</sup> QUARTER 2020

### **Early Warning for Epidemics**

**Prize value: €5 million**

The challenge is to develop a scalable, reliable and cost-effective early warning system to forecast, monitor and ultimately prevent outbreaks of one or more vector-borne diseases.





## Innovative Medicines Initiative (IMI)

The Innovative Medicines Initiative (IMI) is a partnership between the European Union and the European pharmaceutical industry. IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need.



# Innovative Medicines Initiative (IMI)

- Topic 1: [Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches](#)
- Topic 2: [Genome-Environment Interactions in Inflammatory Skin Disease](#)
- Topic 3: [The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use](#)
- Topic 4: [Mitochondrial Dysfunction in Neurodegeneration](#)
- Topic 5: [Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative](#)
- Topic 6: [A sustainable European induced pluripotent stem cell platform](#)
- Topic 7: [Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice](#)
- Topic 8: [Human tumour microenvironment immunoprofiling](#)
- Topic 9: [ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now](#)
- Topic 10: [Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system](#)
- Topic 11: [Translational Safety Biomarker Pipeline \(TransBioLine\): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease](#)
- Topic 12: [Pilot programme on a Clinical Compound Bank for Repurposing: Cardiovascular diseases and diabetes](#)
- Topic 13: [Pilot programme on a Clinical Compound Bank for Repurposing: Respiratory diseases](#)
- Topic 14: [Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases](#)
- Topic 15: [Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases](#)

**deadline 28 february 2018**

# EIT-Health



Search for...



 A body of the European Union

**EIT COMMUNITY**  
Who we are

**ACTIVITIES**  
What we do

**COLLABORATE**  
Work with us

**NEWSROOM**  
What's going on

**INTERACT**  
Connect with us

**IN YOUR LANGUAGE**  
EIT in all EU languages

## EIT - Making innovation happen

- **2018 Call for Proposals** →  
Find the latest information about the 2018 Call
- **EIT Climate-KIC** →
- **EIT Digital** →
- **EIT Food** →
- **EIT Health** →
- **EIT InnoEnergy** →
- **EIT Raw Materials** →



**See the highlights of INNOVEIT 2017 with our Diary Flipbook!**

Thank you for accepting our cookie policy.

Hide this message

More information on cookies



- Home
- About ▾
- Regions ▾
- Partners
- Programmes ▾
- News
- Opportunities
- Events
- Success Stories

Home / About / Our Network /

### About EIT Health

EIT Health promotes healthy living, active ageing and improvements in healthcare.



### About

Goals

**Our Network**

Citizen Engagement

Think Tank

Governance Structure

## Our Network

EIT Health leverages the expertise of more than 140 leading organisations spanning key areas of healthcare, such as pharma, medtech, payers, research institutions and universities.

Connecting our partners' knowledge and competence, we accelerate collaborations in cutting-edge projects, develop health education for the future and speed up new business development.

Our unique, strong and committed partnership is a catalyst for healthcare innovation, cooperating to facilitate new solutions and technologies that benefit European citizens.

As a powerful innovation platform, our network is uniquely positioned in terms of breadth, core-competencies and experience to tackle the health care challenges Europe is facing.

support

universidade de aveiro




theoria poiesis praxis

research

## Other Programmes & Funding Sources



# NIH



U.S. Department of Health & Human Services > National Institutes of Health >

**NIH** National Institutes of Health  
Office of Extramural Research

**Grants & Funding**  
NIH's Central Resource for Grants and Funding Information

Entire Site Search this Site

eRA | Glossary & Acronyms | FAQs | Help

HOME ABOUT GRANTS **FUNDING** POLICY & COMPLIANCE NEWS & EVENTS ABOUT OER

## NIH Guide to Grants and Contracts

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a **table of contents** weekly. Learn more [about the NIH Guide](#) and [subscribe today!](#)  
The **old advanced search** is still available.

**New Features:**

- **Tabular view** - You can now view the search results in table format.
- **Export to excel** - Search results can now be exported to excel for reporting purposes.

Current Search ?

Search Summary or Number

Search Title

Any of these words  
 All of these words  
 This exact word or phrase

Export to  Save this Search 

Refine Your Results ?

Results: 1 to 25 of 1427 Page: 1 of 58 Next Last


Display Results as: **Table** Detailed

Active FOAs Expired FOAs Notices

| Title   | FOA Number | Organization | Released   | Expires    | Activity Code |
|---|------------|--------------|------------|------------|---------------|
| NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 - No Independent Clinical Trials) | PAR-18-436 | NIDCD        | 01-09-2018 | 01-08-2021 | K01           |
| NIDCD Mentored Career Development Award for Postdoctorate Au.D./Ph.D. Audiologists (K01 Clinical Trial Required)          | PAR-18-435 | NIDCD        | 01-09-2018 | 01-08-2021 | K01           |
| NIH StrokeNet Small Business Innovation Clinical Trials   | PAR-18-563 | NINDS        | 01-09-2018 | 01-06-2021 | U44           |

## Fundacion la caixa


Projetos de investigação em biomedicina e saúde, de excelência científica e com maior impacto social, de natureza básica, aplicada ou translacional



- PT e ES
- Categoria A: **única instituição** ou **consórcio** com um **orçamento máximo de € 500.000.**
- Categoria B: **por consórcios** com **abordagem transdisciplinar** com **orçamento máximo de € 1.000.000.**

**deadline 16 march 2018**

## Outros Prémios



**SANTA CASA**  
Misericórdia de Lisboa. Por bons causas.

CONTACTOS 

SANTA CASA AÇÃO SOCIAL CULTURA JOGOS SANTA CASA PATRIMÓNIO SAÚDE OUTRAS ÁREAS INFORMAÇÕES

**Prémios Santa Casa Neurociências**  
Santa Casa da Misericórdia de Lisboa

AS MAIORES BOLSAS À INVESTIGAÇÃO CIENTÍFICA EM NEUROCIÊNCIAS



Procurar...

  **QUÊ NOS LIGAMOS** 231 305 060 **PEDIR KIT**

 **ciroestaminal**  
Ciência para a vida

CÉLULAS ESTAMINAIS A CRIOESTAMINAL OPINIÕES DE ESPECIALISTAS SOLUÇÕES E PREÇOS INVESTIGAÇÃO

30 Outubro, 2017

### ABERTAS AS CANDIDATURAS À 10.ª EDIÇÃO DO PRÉMIO CRIOESTAMINAL

Estão abertas as candidaturas à 10.ª edição do Prémio Crioestaminal, que visa distinguir e apoiar projetos de jovens cientistas na área da Biomedicina. As candidaturas decorrem até ao dia 15 de dezembro de 2017 e a inscrição pode ser submetida através do site da [Associação Viver A Ciência](#).



**deadline 31st  
january 2018**

## Interreg EUROPE

**Main Goal** To help regional and local governments across Europe to develop and deliver better policy.

### Cooperation, collaboration and community engagement

#### 4 Themes/Categories:

Research & innovation

SME competitiveness

Low-carbon economy

Environment & resource efficiency

#### 3 types of beneficiaries:

**Public authorities** – local, regional and national

**Managing authorities/intermediate bodies** - in charge of the Investment for Growth and Jobs programmes or European Territorial Cooperation

**Agencies, research institutes, thematic and non-profit organisations** – although not our main target group, these types of organisations can also work with Interreg Europe by *first* engaging with their local policymakers in order to identify options for collaboration with Interreg Europe



3 partners of at least 2 different regions  
**28 EU countries + Norway+ Switzerland**

co-finance up to 85% of project activities  
budget around 1-2M€ per project

**Forthcoming Call – 4<sup>th</sup> call (May - mid-June 2018) to be confirmed**  
<https://www.interregeurope.eu/projects/apply-for-funding/>

- 2 phases :**
- Phase 1 - experience, ideas and know-how sharing, about how best to deal with the issue at hand. Each partner region must:
- Produce an action plan
  - Set up a stakeholder group
  - Participate in the Interreg Europe Policy Learning Platform

Phase 2 - **monitoring progress of the implementation** of their action plan and report to the lead partner. Pilot actions may be supported during this period.

## Interreg SUDOE

At least **3 partners**, public and private non-profit organizations and companies, with the exception of large companies

On going call...

➔ Two phase calls:

➔ Project's Idea presentation ( relevance and expected results)

(online submission\* using the languages of the participating partners + paperback copy & commitment declaration)

### (Evaluation Step)

➔ 2. Detailed submission of the 1st phase approved proposals

(online submission\* using the languages of the participating partners + paperback copy & commitment declaration)



\*UA já está registada como Unidade. Necessidade de Registo individual e associação da entidade  
<http://interreg-sudoe.eu/prt/projetos/apresentar-o-meu-projeto>






**Forthcoming calls**  
**3rd call – beginning 2018**

**Forthcoming calls**  
**4th call – end 2018**

<http://www.interreg-sudoe.eu/prt/projetos/apresentar-o-meu-projeto>





Homepage / Projetos / As convocatórias / Encontre sóci@s / Consulte as ideias de projecto existentes

## Projetos

### As convocatórias

[Calendário](#)

[Apresentar o meu projeto](#)

[Ferramentas](#)

[Encontre sóci@s](#)

[Consulte as ideias de projecto existentes](#)

[Proponha a sua ideia de projeto](#)

[Primeira convocatória \(TERMINADA\)](#)

[Segunda convocatória \(EM CURSO\)](#)

[Os projectos aprovados](#)

[Lista de beneficiários](#)

## Consulte as ideias de projecto existentes



### Biotechnology - Regenerative medicine, tissue engineering and clinical application


ÚLTIMA REVISÃO: 22 MAR 2017

|                          |   |
|--------------------------|---|
| <b>INSTITUIÇÃO</b>       | Vetherapy - Research and Development in Biotechnology   |
| <b>PESSOA DE CONTATO</b> | Pedro Carvalho <a href="#">Mostrar email</a>  |
| <b>ENDEREÇO</b>          | Av. José Sousa Fernandes, Campus Universitário - Bloco B  |
| <b>CIDADE</b>            | Coimbra   |
| <b>CÓDIGO POSTAL</b>     | 3020-210  |
| <b>PAÍS</b>              | Portugal  |
| <b>REGIÃO</b>            | Centro  |
| <b>PRIORIDADE</b>        | Objetivo 1b1: Reforçar o funcionamento sinérgico e em rede da I+D+i a nível transnacional nos setores específicos do Sudoe a partir da especialização inteligente |

## Descrição

We are a biotech company acting in the veterinary clinical scenario. We develop different regenerative products based on stem cells, growth factors and biomaterials technology and are always looking for innovative therapeutic products/technologies that





The screenshot shows a web browser window with the URL <https://www.interregurope.eu/search/>. The browser's address bar shows a search for "Pesquisar". The page features a navigation bar with four categories: "Research and innovation" (orange), "SME competitiveness" (teal), "Low carbon economy" (green), and "Environment and resource efficiency" (light green). On the left side, there is a sidebar with filters: "Good practice", "Library", "News", "Events", "More options", "Themes", and "Countries/regions", each with a plus sign icon. Below the filters is a "Search" button. The main content area is titled "Trending project ideas" and displays three project cards. Each card has a lightbulb icon in a circle and a star icon in the top right corner. The first card is titled "RICH-DEST: Railways ..." and is submitted by Manos Vougioukas from Greece. The second card is titled "REDDERE+" and is submitted by Jonathan Rodriguez from Spain. The third card is titled "STAR Cities -Sustainable..." and is submitted by Camille Chowah from France.

https://www.interregurope.eu/search/ 80% Pesquisar

Research and innovation SME competitiveness Low carbon economy Environment and resource efficiency

Good practice  
 Library  
 News  
 Events  
 More options  
 Themes  
 Countries/regions

Search

### Trending project ideas



**RICH-DEST: Railways ...**

To preserve, restore, safeguard, showcase & deploy the very rich cultural &...

Submitted by: Manos Vougioukas  
Greece (Ελλάδα) 🇬🇷



**REDDERE+**

REDDERE is all about optimum SME performance within the scope of sustainable...

Submitted by: Jonathan Rodriguez  
Spain (España) 🇪🇸



**STAR Cities -Sustainable...**

Many European territories have developed strong relations with a river, that...

Submitted by: Camille Chowah  
France 🇫🇷



## Interreg ES-PT ( POCTEP)

- Espanha:** Ourense, Pontevedra, Zamora, Salamanca, Cáceres, Badajoz, Huelva, A Coruña, Lugo, Ávila, León, **Valladolid**, Cádiz, Córdoba e Sevilla.
- Portugal:** Alto Minho, Cávado, Terras Trás-os-Montes, Douro, Beiras e Serra de Estrela, Beira Baixa, Alto Alentejo, Alentejo Central, Baixo Alentejo, Algarve, Ave, Alto Tâmega, Tâmega e Sousa, Área Metropolitana do Porto, Viseu Dão-Lafões, Região de Coimbra, Médio Tejo, Região de Aveiro, Região de Leiria, Oeste e Alentejo Litoral.

### Forthcoming call

**28/02/2018 a 28/03/2018**

<http://www.poctep.eu/pt-pt/2014-2020/an%C3%BAnncio-da-2%C2%AA-convocat%C3%B3ria-poctep-20142020-para-apresenta%C3%A7%C3%A3o-de-projetos>





## Interreg ES-PT ( POCTEP)

### actions in favor of research, development and innovation

- Research and innovation activities, including networking.
- Transfer of technology and university-business cooperation, especially for the benefit of SMEs.
- Research and innovation processes in SMEs.

### actions related to business development and the promotion of quality employment

- Promotion of entrepreneurship and entrepreneurship in SMEs.
- Business development of SMEs, support for mentoring networks and support for entrepreneurship and incubation.
- Self-employment, entrepreneurship and entrepreneurship, including microenterprises and entrepreneurial SMEs
- Promotion of internationalization
- Mobility of workers

### environment and energy and ecological infrastructures

- Adaptation to climate change and risk prevention and management. Development and promotion of the tourism potential of natural spaces. Protection and promotion of cultural assets and natural heritage. Treatment of household waste. Management and conservation of drinking water. Integrated pollution prevention and control



# COSME- EU programme for the Competitiveness of Enterprises and Small and Medium-sized Enterprises (SMEs)

## ACCESS TO FINANCE



One of **COSME's** main objectives is to provide enhanced access to finance for SMEs in different phases of their lifecycle: creation, expansion or business transfer. In order to achieve this objective, the EU will mobilise loans and equity investments for SMEs.

- Through the **Loan Guarantee Facility**, the programme will provide guarantees and counter-guarantees to financial institutions (e.g. guarantee societies, banks, leasing companies) so they can provide more loan and lease finance to SMEs. It is expected that COSME will enable between 220 000 and 330 000 SMEs to obtain financing for a total value of between €14 and €21 billion.
- Through the **Equity Facility for Growth**, the programme will provide risk capital to equity funds investing in SMEs mainly in the expansion and growth-stage phases. The Facility should help between 360 and 560 firms to receive equity investment with an overall volume invested ranging from € 2.6 to € 4 billion.

## ACCESS TO MARKETS



**COSME** provides support to European enterprises so that they can benefit from the EU's single market and make the most of opportunities offered by markets outside the EU.

**COSME** funds the **Enterprise Europe Network (EEN)** consisting of over 600 offices in more than 50 countries helping SMEs find business and technology partners, understand EU legislation and access EU financing.

**COSME** also funds web tools specifically designed for enterprises development such as **Your Europe Business Portal** or the **SME Internationalisation Portal**. The first provides practical online information for entrepreneurs who want to become active in another Member State. The latter puts the emphasis on support measures for companies which want to develop their business outside Europe.

**COSME** finances the **ASEAN, China and MERCOSUR Intellectual Property Rights (IPR) SME Helpdesks** that offer advice and support to European SMEs facing difficulties in IPR issues, standards or public procurement rules in those geographical areas.

The programme also provides financial assistance to the **EU-Japan Centre for Industrial Cooperation**, to promote all forms of industrial trade and investment cooperation by disseminating information on how to access the Japanese market, facilitating exchanges of experience and know-how between EU and Japanese businesses.

## CREATING BETTER FRAMEWORK CONDITIONS FOR COMPETITIVENESS



**COSME** supports actions to improve the framework conditions in which enterprises operate, in particular SMEs, by reducing unnecessary administrative and regulatory burdens. Such actions may include measuring the impact of relevant Union law on SMEs, developing smart and business friendly regulation for them and reinforcing the use of the "Think Small First" principle for policy-making at national and regional level.

**COSME** supports the emergence of competitive industries with market potential, by helping SMEs to take-up new business models and integrate into new value chains. The programme complements the actions of Member States in areas with high growth potential such as the tourism sector.

**COSME** promotes the development of worldclass clusters in the EU, fostering cluster excellence and internationalisation with an emphasis on cross-sectoral cooperation, notably in support of emerging industries. The programme also aims at accelerating the digitalisation of the business community and promoting e-skills and e-leadership.

## ENCOURAGING ENTREPRENEURSHIP



**COSME** backs the implementation of the **Entrepreneurship 2020 Action Plan** through a wide range of activities. These include mobility exchanges, research, best practices diffusion and pilot projects in areas such as entrepreneurship education, mentoring or the development of guidance and support services for new and potential entrepreneurs, including young, women and senior entrepreneurs.

**Erasmus for Young Entrepreneurs** is for instance a cross-border exchange scheme which aims to help new and aspiring entrepreneurs acquire relevant skills to run and grow a business by working with an experienced entrepreneur in another country for one to six months. It increases their know-how and fosters cross-border transfer of knowledge and experience between entrepreneurs.

**COSME** especially focuses on digital entrepreneurship to help European businesses drive their digital transformation and fully benefit from the unprecedented new opportunities created in the digital era, which are crucial for their competitiveness and growth.



## Eurostars



Eurostars is a programme that supports research-performing small and medium enterprises, which develop innovative products, processes and services, to gain competitive advantage.

Eurostars projects are:

- transnational,
- started and led by an SME,
- involve at least two partners from two different Eurostars participating country,
- involve at least one other partner from another Eurostars participating country, and
- last no longer than three years.

Within two years of completion the product of research should be ready for market introduction.

## Useful Links & more information

- **Horizon 2020 website**

<http://ec.europa.eu/programmes/horizon2020/en>

- **Participant Portal**


<http://ec.europa.eu/research/participants/portal/desktop/en/home.html>

- **Funded Projects database**

([http://cordis.europa.eu/projects/home\\_en.html](http://cordis.europa.eu/projects/home_en.html))

- **Partners**

<https://cordis.europa.eu/partners/web/guest/home>



The screenshot shows the 'Participant Portal H2020 Online Manual' interface. The main content area is organized into several sections:

- Grants**
  - Applying for funding*: Find a call, Find partners, Register an organisation, Submit a proposal
  - Evaluation & Grant signature*: Eligibility check, Evaluation of proposals, Grant preparation, Grant signature
  - Grant management*: Keeping records, Amendments, Reports & payment requests, Deliverables, Dissemination & exploitation of results, Check, audits, reviews & investigations
- Working as an expert**: Expert registration, Contracting & payment, Expert roles & tasks
- Cross-cutting issues**: International cooperation, Ethics, Intellectual property, Gender, SMEs, Links to regional policy

The left navigation menu includes: My Area - User account & roles, Login with ECAS, Roles & access rights, Terms and Conditions of Use, Grants, Applying for funding, Find a call, Horizon 2020 structures and budgets, What you need to know about Horizon 2020 calls, Find partners or apply as individual, Register in the Beneficiary Register, Registration of your organisation, Lead appointment, Validation of potential beneficiaries, Financial viability check, Data update, Certifications, Submit a proposal, From evaluation to grant signature, Eligibility check, Evaluation of proposals, Eligibility and evaluation criteria, Evaluation process and results.



**Contact us!**

## Vice-Rector for Research and Doctoral School

**Prof. Dr. José Fernando Mendes** - [jfmendes@ua.pt](mailto:jfmendes@ua.pt)

**Luísa Fernandes Sal** - [luisa.fernandes@ua.pt](mailto:luisa.fernandes@ua.pt)

Phone: (+351) 234370848, ext. 52113

Fax: (+351) 234370089

**Tatiana Lima Costa** - [tatiana.costa@ua.pt](mailto:tatiana.costa@ua.pt)

Phone: (+351) 234247190, ext. 22016

Fax: (+351) 234370089

**Vera Fernandes** - [verafernandes@ua.pt](mailto:verafernandes@ua.pt)

Phone: (+351) 234401571, ext. 22098

Fax: (+351) 234370089



# Thank You!